Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study

Jun 2022 | From Akero Therapeutics

Efruxifermin (EFX), a long-acting FGF21 analog as a therapy for NASH

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment significantly reduced markers of collagen synthesis and fibrosis and normalized levels of Pro-C3 in patients with livery fibrosis associated with NASH

Jun 2021 | FROM AKERO THERAPEUTICS

Efruxifermin is Associated With Improved Glucose Metabolism in Patients With NASH and Type 2 Diabetes

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.